DexCom (NASDAQ:DXCM) Director Nicholas Augustinos Sells 1,550 Shares of Stock

Key Points

• DexCom director Nicholas Augustinos sold 1,550 shares at an average price of $84.02, worth $130,231, reducing his direct stake by 4.15%. The sale was made under a pre-arranged Rule 10b5-1 trading plan, following an additional sale of 6,539 shares the next day.
• DexCom reported quarterly earnings of $0.70 per share, beating estimates of $0.61, while revenue rose 13.1% year over year to $1.31 billion. Analysts expect full-year earnings of $2.64 per share.
• Wall Street maintains a favorable view, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $88.71; institutional investors own 97.75% of DexCom’s shares.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) Director Nicholas Augustinos sold 1,550 shares of the business's stock in a transaction on Monday, September 14th. The stock was sold at an average price of $84.02, for a total value of $130,231.00. Following the completion of the transaction, the director directly owned 35,832 shares in the company, valued at approximately $3,010,604.64. This represents a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nicholas Augustinos also recently made the following trade(s):

• On Tuesday, September 15th, Nicholas Augustinos sold 6,539 shares of DexCom stock. The shares were sold at an average price of $84.04, for a total value of $549,537.56.

DexCom Stock Performance

Shares of NASDAQ DXCM traded up $0.89 during mid-day trading on Wednesday, reaching $87.34. 3,541,995 shares of the company's stock were exchanged, compared to its average volume of 5,115,788. The firm has a market capitalization of $32.96 billion, a price-to-earnings ratio of 34.52, a price-to-earnings-growth ratio of 1.42 and a beta of 1.42. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The firm has a 50-day moving average price of $83.25 and a two-hundred day moving average price of $72.98.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm's quarterly revenue was up 13.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.48 EPS. Analysts predict that DexCom, Inc. will post 2.64 EPS for the current year.

Hedge Funds Weigh In On DexCom

Several large investors have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of DexCom by 15.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company's stock valued at $758,487,000 after buying an additional 1,515,702 shares in the last quarter. Geode Capital Management LLC raised its holdings in DexCom by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company's stock valued at $727,842,000 after acquiring an additional 42,411 shares during the period. Norges Bank purchased a new stake in shares of DexCom during the fourth quarter worth $483,356,000. Janus Henderson Group PLC lifted its position in shares of DexCom by 32.3% during the first quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company's stock worth $166,077,000 after acquiring an additional 645,534 shares in the last quarter. Finally, Legal & General Group Plc bought a new position in shares of DexCom in the second quarter worth $173,237,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Royal Bank Of Canada increased their target price on shares of DexCom from $85.00 to $90.00 and gave the company an "outperform" rating in a research report on Friday, July 31st. BTIG Research reaffirmed a "buy" rating and issued a $90.00 price target (up from $80.00) on shares of DexCom in a report on Friday, July 31st. Benchmark upped their price objective on DexCom from $77.00 to $82.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Citigroup reissued a "buy" rating and set a $88.00 price objective (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Finally, Argus raised their target price on DexCom from $86.00 to $96.00 and gave the stock a "buy" rating in a research report on Tuesday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $88.71.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company's products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.